Compare · CCEL vs LSTA
CCEL vs LSTA
Side-by-side comparison of Cryo-Cell International Inc. (CCEL) and Lisata Therapeutics Inc. (LSTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CCEL and LSTA operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- CCEL is the larger of the two at $83.3M, about 2.5x LSTA ($32.9M).
- Over the past year, CCEL is down 36.3% and LSTA is up 41.1% - LSTA leads by 77.3 points.
- LSTA has been more active in the news (8 items in the past 4 weeks vs 1 for CCEL).
- Company
- Cryo-Cell International Inc.
- Lisata Therapeutics Inc.
- Price
- $3.41-1.16%
- $3.64+8.01%
- Market cap
- $83.3M
- $32.9M
- 1M return
- -2.85%
- +11.31%
- 1Y return
- -36.26%
- +41.09%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 1
- 8
- Recent ratings
- 0
- 0
Cryo-Cell International Inc.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Latest CCEL
- VP Finance, CFO Taymans Jill M exercised 7,500 shares at a strike of $3.10, increasing direct ownership by 17% to 52,896 units (SEC Form 4)
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
- Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives NYSE American Continued Listing Notice
- SEC Form 10-K filed by Cryo-Cell International Inc.
- Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025
Latest LSTA
- SEC Form SC 14D9 filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Other Events
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- SEC Form 10-Q filed by Lisata Therapeutics Inc.
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.